Ladenburg Thalmann analyst Matthew Kaplan maintains United Therapeutics (NASDAQ:UTHR) with a Buy and lowers the price target from $285 to $256.
Ladenburg Thalmann Maintains Buy on United Therapeutics, Lowers Price Target to $256
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.